Moderna shares fall sharply after detailed late-stage data for its personalized melanoma vaccine with Merck was released.
Moderna shares fell more than 25% on Thursday, erasing about $24 billion in market value. Detailed trial results showed the intismeran vaccine combined with Keytruda reduced the risk of cancer recurrence or death by 42% versus Keytruda alone. The data were released after leaking on an oncology website earlier in the day.
29
Divergence score
This event sits in the top 14% of divergence this week. 3 outlets covered it, splitting into 3 framing camps across 3 bias groups.
3 camps
3 bias groups
Market signalBETA
The spectrum · how 3 outlets placed this story
LeftCenterRight
Globe and Mail
Reuters
Financial Times
Supportive of action
Neutral
Dismissive
Critical
Alarmist
International angle
Widest split · the two outlets furthest apart, and who published first
Furthest apart on this story
Globe and Mail
Moderna shares sink over 25% as cancer vaccine data triggers ‘sell-the-news’ retreat
Analyst-sourced sell-the-news explanation · neutral
Financial Times
Moderna shares sink after leaked cancer data missed expectations
Data disappointed expectations · negative
First to report
- Globe and Mailfirst
- Reuters+6 min
- Financial Times+1.4 h
By each outlet's earliest publish time in this story. Feeds that index slowly can appear later than they printed.
The split, in one line
Two outlets call the drop a sell-the-news reaction to solid data; the FT says the leaked data missed expectations, framing the fall as a verdict on the results rather than on investor positioning.
How each outlet covered it
Lightly covered so far
Too few outlets to map a left-right split. Here is each take as it stands.
Sparse coverage · 3 outlets
“Moderna shares sink over 25% as cancer vaccine data triggers ‘sell-the-news’ retreat”
“Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat - Reuters”
“Moderna shares sink after leaked cancer data missed expectations”
4 tracked claims across 3 outlets
Fact ledger
All4Claimed1Corroborated3
2/3
Claimed
The share decline was a 'sell-the-news' reaction to solid data rather than disappointment in the results.
Corroborated
Disputed
3 more tracked claimsSign up free to see the full ledger